BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2558 related articles for article (PubMed ID: 32755310)

  • 1. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle.
    Dowman JK; Hopkins LJ; Reynolds GM; Nikolaou N; Armstrong MJ; Shaw JC; Houlihan DD; Lalor PF; Tomlinson JW; Hübscher SG; Newsome PN
    Am J Pathol; 2014 May; 184(5):1550-61. PubMed ID: 24650559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.
    Garcia-Jaramillo M; Spooner MH; Löhr CV; Wong CP; Zhang W; Jump DB
    PLoS One; 2019; 14(4):e0214387. PubMed ID: 30943218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Western Diet-Induced Nonalcoholic Steatohepatitis in Ldlr-/- Mice Reversible?
    Lytle KA; Jump DB
    PLoS One; 2016; 11(1):e0146942. PubMed ID: 26761430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease.
    Kim TH; Banini BA; Asumda FZ; Campbell NA; Hu C; Moser CD; Shire AM; Han S; Ma C; Krishnan A; Mounajjed T; White TA; Gores GJ; LeBrasseur NK; Charlton MR; Roberts LR
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G333-G344. PubMed ID: 32683952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice.
    Dowman JK; Hopkins LJ; Reynolds GM; Armstrong MJ; Nasiri M; Nikolaou N; van Houten EL; Visser JA; Morgan SA; Lavery GG; Oprescu A; Hübscher SG; Newsome PN; Tomlinson JW
    Endocrinology; 2013 Dec; 154(12):4536-47. PubMed ID: 24080367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice.
    Lytle KA; Wong CP; Jump DB
    PLoS One; 2017; 12(4):e0173376. PubMed ID: 28422962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of altered hepatic gene expression in American lifestyle-induced obesity syndrome diet-fed mice with metabolic changes during NAFLD development and progression.
    Iannone V; Lok J; Babu AF; Gómez-Gallego C; Willman RM; Koistinen VM; Klåvus A; Kettunen MI; Kårlund A; Schwab U; Hanhineva K; Kolehmainen M; El-Nezami H
    J Nutr Biochem; 2023 May; 115():109307. PubMed ID: 36868506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.
    Krishnan A; Abdullah TS; Mounajjed T; Hartono S; McConico A; White T; LeBrasseur N; Lanza I; Nair S; Gores G; Charlton M
    Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G666-G680. PubMed ID: 28232454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
    Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic phenotype and adipose and liver features in a high-fat Western diet-induced mouse model of obesity-linked NAFLD.
    Luo Y; Burrington CM; Graff EC; Zhang J; Judd RL; Suksaranjit P; Kaewpoowat Q; Davenport SK; O'Neill AM; Greene MW
    Am J Physiol Endocrinol Metab; 2016 Mar; 310(6):E418-39. PubMed ID: 26670487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer.
    Tsuchida T; Lee YA; Fujiwara N; Ybanez M; Allen B; Martins S; Fiel MI; Goossens N; Chou HI; Hoshida Y; Friedman SL
    J Hepatol; 2018 Aug; 69(2):385-395. PubMed ID: 29572095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of liquid fructose/sucrose in regulating the hepatic transcriptome in a high-fat Western diet model of NAFLD.
    Luo Y; Woodie LN; Graff EC; Zhang J; Fowler S; Wang X; Wang X; O'Neill AM; Greene MW
    J Nutr Biochem; 2023 Feb; 112():109174. PubMed ID: 36280127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nordihydroguaiaretic Acid, a Lignan from
    Chan JKW; Bittner S; Bittner A; Atwal S; Shen WJ; Inayathullah M; Rajada J; Nicolls MR; Kraemer FB; Azhar S
    J Pharmacol Exp Ther; 2018 May; 365(2):281-290. PubMed ID: 29472517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease.
    Larner DP; Morgan SA; Gathercole LL; Doig CL; Guest P; Weston C; Hazeldine J; Tomlinson JW; Stewart PM; Lavery GG
    Endocrinology; 2016 Sep; 157(9):3493-504. PubMed ID: 27384305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
    Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
    Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer.
    Jump DB; Depner CM; Tripathy S; Lytle KA
    Adv Nutr; 2015 Nov; 6(6):694-702. PubMed ID: 26567194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
    Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
    J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 128.